Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction-Reference-Cited by-同舟云学术

Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction

Published:2015-05-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Su Qiang¹,Nyi Tun Swe¹,Li Lang¹

Affiliation:

1. The First Affiliated Hospital of Guangxi Medical University; Department of Cardiology; No. 6, Shuang Yong Load Nanning Guangxi China 530021

Publisher

Wiley

Subject

Pharmacology (medical)

Reference82 articles.

1. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction;Desmet;European Heart Journal,2011

2. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial;Fokkema;Circulation. Cardiovascular Interventions,2009

3. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention;Grygier;The American Journal of Cardiology,2011

4. Ji ZG Han JM Liu G Liu K Effect of adenosine on ischemia-reperfusion injury during percutaneous coronary intervention Journal of Clinical Rehabilitative Tissue Engineering Research 2007 10399 403

5. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction;Marzilli;Circulation,2000

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic Changes in Ion Channels during Myocardial Infarction and Therapeutic Challenges;International Journal of Molecular Sciences;2024-06-12

2. No-Reflow Prediction in Acute Coronary Syndrome During Percutaneous Coronary Intervention: The NORPACS Risk Score;Circulation: Cardiovascular Interventions;2024-04

3. Mitigating the risk of flow deterioration by deferring stent optimization in STEMI patients with large thrombus burden: Insights from a prospective cohort study;BMC Cardiovascular Disorders;2023-10-12

4. Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation;Frontiers in Cardiovascular Medicine;2023-03-10

5. Predictores de fenómeno de no reflujo en infarto agudo del miocardio con elevación del segmento ST;Archivos de Cardiología de México;2022-11-24